| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Over the last 12 months, insiders at Mereo BioPharma Group plc have bought $0 and sold $0 worth of Mereo BioPharma Group plc stock.
On average, over the past 5 years, insiders at Mereo BioPharma Group plc have bought $0 and sold $3.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2024-09-13 | Sale | Scots-Knight Denise | Chief Executive Officer | 60,046 0.0454% | $4.22 | $253,454 | -35.98% | |
| 2024-09-13 | Sale | Sermon Charles | General Counsel | 20,946 0.0158% | $4.22 | $88,413 | -35.98% | |
| 2024-09-13 | Sale | Fox Christine Ann | Chief Financial Officer | 19,158 0.0145% | $4.22 | $80,866 | -35.98% | |
| 2024-09-13 | Sale | Lewicki John A. | Chief Scientific Officer | 10,937 0.0083% | $4.22 | $46,165 | -35.98% | |
| 2024-09-13 | Sale | Hughes-Wilson Alexandra | See Remarks | 100,312 0.0759% | $4.22 | $423,417 | -35.98% | |
| 2024-09-12 | Sale | Scots-Knight Denise | Chief Executive Officer | 28,611 0.0229% | $4.47 | $127,968 | -37.59% | |
| 2024-09-12 | Sale | Sermon Charles | General Counsel | 9,980 0.008% | $4.47 | $44,638 | -37.59% | |
| 2024-09-12 | Sale | Hughes-Wilson Alexandra | See Remarks | 47,798 0.0383% | $4.47 | $213,786 | -37.59% | |
| 2024-09-12 | Sale | Fox Christine Ann | Chief Financial Officer | 9,128 0.0073% | $4.47 | $40,827 | -37.59% | |
| 2024-09-12 | Sale | Lewicki John A. | Chief Scientific Officer | 5,212 0.0042% | $4.47 | $23,312 | -37.59% | |
| 2024-08-22 | Sale | PAKIANATHAN DEEPIKA | director | 105,244 0.0836% | $4.43 | $466,210 | -36.36% | |
| 2024-06-26 | Sale | Scots-Knight Denise | Chief Executive Officer | 92,273 0.0561% | $3.39 | $313,101 | -0.86% | |
| 2024-06-26 | Sale | Sermon Charles | General Counsel | 32,187 0.0196% | $3.39 | $109,217 | -0.86% | |
| 2024-06-26 | Sale | Fox Christine Ann | Chief Financial Officer | 29,439 0.0179% | $3.39 | $99,892 | -0.86% | |
| 2024-06-26 | Sale | Lewicki John A. | Chief Scientific Officer | 16,808 0.0102% | $3.39 | $57,033 | -0.86% | |
| 2024-06-26 | Sale | Hughes-Wilson Alexandra | See Remarks | 22,968 0.014% | $3.39 | $77,935 | -0.86% | |
| 2024-06-25 | Sale | Scots-Knight Denise | Chief Executive Officer | 40,712 0.027% | $3.69 | $150,386 | -0.71% | |
| 2024-06-25 | Sale | Sermon Charles | General Counsel | 14,202 0.0094% | $3.69 | $52,461 | -0.71% | |
| 2024-06-25 | Sale | Fox Christine Ann | Chief Financial Officer | 12,990 0.0086% | $3.69 | $47,984 | -0.71% | |
| 2024-06-25 | Sale | Lewicki John A. | Chief Scientific Officer | 7,416 0.0049% | $3.69 | $27,394 | -0.71% |
| Increased Positions | 37 | +28.91% | 30M | +29.68% |
| Decreased Positions | 57 | -44.53% | 68M | -67.79% |
| New Positions | 22 | New | 12M | New |
| Sold Out Positions | 37 | Sold Out | 61M | Sold Out |
| Total Postitions | 108 | -15.63% | 62M | -38.11% |
| Janus Henderson Group Plc | $8,308.00 | 2.05% | 16.29M | -1M | -7.91% | 2025-09-30 |
| Rubric Capital Management Lp | $7,807.00 | 1.92% | 15.31M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $4,814.00 | 1.19% | 9.44M | 0 | 0% | 2025-09-30 |
| Mangrove Partners Im, Llc | $3,973.00 | 0.98% | 7.79M | -845,905 | -9.79% | 2025-09-30 |
| Aberdeen Group Plc | $2,825.00 | 0.7% | 5.54M | +3M | +82.86% | 2025-09-30 |
| 683 Capital Management, Llc | $2,486.00 | 0.61% | 4.88M | +525,000 | +12.07% | 2025-09-30 |
| Rock Springs Capital Management Lp | $2,331.00 | 0.57% | 4.57M | +105,357 | +2.36% | 2025-09-30 |
| Clearline Capital Lp | $1,955.00 | 0.48% | 3.83M | +216,000 | +5.97% | 2025-09-30 |
| Alkeon Capital Management Llc | $1,886.00 | 0.47% | 3.7M | -1M | -21.29% | 2025-09-30 |
| Morgan Stanley | $1,707.00 | 0.42% | 3.35M | +3M | +326.08% | 2025-09-30 |